Friday, February 09, 2024 5:59:27 PM
Any comments I make represent my opinions only. My opinions are based on facts I am aware of at the present time. As facts change (as they often do), so do my opinions. Do not mistake my opinions for investment advise, do your own DD.
Recent GANX News
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 04/24/2024 01:25:00 PM
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer • GlobeNewswire Inc. • 04/08/2024 01:25:00 PM
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/01/2024 01:25:00 PM
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Gain Therapeutics to Present at Public Ventures Discovery Day • GlobeNewswire Inc. • 03/15/2024 06:30:11 PM
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 02/27/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:17 PM
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight • GlobeNewswire Inc. • 02/14/2024 05:29:34 PM
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 02:56:04 PM
- Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:26:33 PM
- Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2024 09:09:27 PM
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024 • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/02/2024 05:15:12 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:03 PM
- Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model • GlobeNewswire Inc. • 12/01/2023 01:00:00 PM
- Gain Therapeutics to Participate in AI Driven Drug Discovery Summit • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option • GlobeNewswire Inc. • 11/24/2023 06:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/24/2023 11:07:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 10:27:26 PM
- Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants • GlobeNewswire Inc. • 11/21/2023 01:54:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/20/2023 09:22:52 PM
- Gain Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 11/20/2023 09:03:43 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM